|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||165.55 - 168.47|
|52 Week Range||136.61 - 181.72|
|PE Ratio (TTM)||13.60|
|Earnings Date||Apr 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||194.07|
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
LabCorp® (LH) and the Mount Sinai Health System today announced a significant milestone in achieving their common goal of improving laboratory services and patient care. LabCorp, a leading global life sciences company, and Mount Sinai, one of the largest health systems in metropolitan New York City, have begun to implement a program to standardize and optimize inpatient laboratory services across the Mount Sinai system. LabCorp and Mount Sinai have entered into a contract that will enhance laboratory operations at each of Mount Sinai’s seven acute care hospitals.
This latest deal reflects the rise of retail health clinics, which are touted for their ability to provide accessible care.
Walgreens and LabCorp® (LH) today announced the expansion of their LabCorp at Walgreens collaboration into Florida. Ten new LabCorp patient service centers will open within Walgreens stores in April and May, with four serving the Gainesville market and two each serving the Palm Beach County, Pasco County, and Orlando areas. These sites are in addition to five Denver-area locations and one in Morrisville, North Carolina, that opened in 2017, as part of LabCorp’s nearly 2,000 patient service center network across the U.S. The co-branded LabCorp at Walgreens sites offer LabCorp patient services in a secure, comfortable environment for specimen collection, located near the pharmacy area inside the Walgreens store.
The expansion of LabCorp's partnership with Walgreens demonstrates the health care industry's push to connect directly with consumers.
Labcorp's (LH) multi-year LaunchPad project holds enough promise for growth. Good news is that the company already grossed savings worth $20 million from the same in 2017.
BUFFALO, N.Y., April 12, 2018-- OmniSeq ®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation’ s participation in ...
LabCorp has officially announced its expansion into new space at the former GlaxoSmithKline space in Research Triangle Park and the new jobs that will come with it.
LabCorp® announced today that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below.
A lawsuit has been filed alleging that LabCorp has violated the Telephone Consumer Protection Act by making automated phone calls.
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
Through the partnership, LabCorp will offer a range of services, including technical services for Appalachian Regional's hospital-based labs.
LabCorp® and Appalachian Regional Healthcare have entered into a multi-year, comprehensive laboratory partnership. Through the collaboration, LabCorp Diagnostics will provide technical services for Appalachian Regional Healthcare’s hospital-based labs, reference testing services for its entire network of facilities and clinicians, and access to enhanced information technology and data analytics to ...
Per the new deal with Interpace, Dianon Pathology, member of the LabCorp (LH) Specialty Testing Group, is supposed to perform the thyroid biopsy analysis.
NEW YORK, March 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
PARSIPPANY, N.J., March 20, 2018-- Interpace Diagnostics Group, Inc., a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services ...
Theranos and two of its principal officers were charged by the SEC with an "elaborate, years-long fraud" that raised $700 million for the needles-free blood diagnostics company that once was the toast of the media and investment world.
A business unit of Laboratory Corporation of America Holdings has created a division to focus on offerings to help further the development of biologic drugs, the Burlington-based company said. The creation of the immunology and immunotoxicology unit by Covance Drug Development comes as LabCorp has focused on expanding its operations beyond laboratory diagnostics in order to become a global life sciences company. LabCorp (LH) acquired Covance for $6.2 billion in 2015.